e-learning
resources
Paris 2018
Wednesday, 19.09.2018
Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum Club cell16 levels as a biomarker in tobacco-smoke COPD and biomass-smoke COPD
V. Veerapaneni (mysore, India), J. Bs (mysore, India), C. S.K (mysore, India), L. K.S (mysore, India), K. Sivakoti (mysore, India), R. Tirumulappa (mysore, India), M. P.A (mysore, India)
Source:
International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Session:
Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Session type:
Poster Discussion
Number:
5479
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Veerapaneni (mysore, India), J. Bs (mysore, India), C. S.K (mysore, India), L. K.S (mysore, India), K. Sivakoti (mysore, India), R. Tirumulappa (mysore, India), M. P.A (mysore, India). Serum Club cell16 levels as a biomarker in tobacco-smoke COPD and biomass-smoke COPD. 5479
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Post partum
dyspnoea: look beyond the lungs
A 34-year-old male smoker with exertional dyspnoea
Related content which might interest you:
Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD
Source: International Congress 2017 – COPD biomarkers
Year: 2017
Increased serum endotoxin levels as biomarker in acute exacerbations of COPD.
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Blood biomarkers in asthma and COPD
Source: International Congress 2017 – PG6 Assessing and monitoring airway inflammation in asthma and chronic obstructive pulmonary disease
Year: 2017
Plasma biomarkers and response to therapy at exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 39s
Year: 2007
Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Serum periostin in patients hospitalized for COPD exacerbations
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap
Source: Annual Congress 2013 –Is it really asthma?
Year: 2013
Serum G-CSF is a non-invasive biomarker classifying bacterial/neutrophilic COPD exacerbations
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020
Sputum biomarkers of inflammation in smokers and subjects with COPD
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Metabolomics identifies biomarkers of exacerbations in smokers with and without COPD
Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases
Year: 2020
Prevalence of exacerbation in COPD patients with chronic bronchitis and association with elevated serum inflammatory biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Visfatin as a possible serum biomarker in COPD
Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases
Year: 2019
Differences in plasma and sputum biomarkers between COPD and COPD–asthma overlap
Source: Eur Respir J 2014; 43: 421-429
Year: 2013
Serum vitamin D3 level correlates with FEV1 in patients with advanced COPD
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
Effects of erdosteine on serum biomarker concentrations at COPD exacerbation
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010
Serum sirtuin-1 is reduced in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Association of serum pneumoproteins with clinical course of COPD
Source: International Congress 2017 – COPD biomarkers
Year: 2017
Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
Source: International Congress 2016 – Inflammatory biomarkers in airway diseases
Year: 2016
Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory
Source: Annual Congress 2013 –COPD treatment
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept